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An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-
induced selection of mutants conferring resistance to protease inhibitors has been shown both in vivo and in vitro. A specific mutation, A156T has
been shown to confer high-level resistance to several such agents (BILN2061, VX-950, SCH446211 (SCH6) and SCH503034). Here we report the
presence of the A156T mutation in close to 1% of NS3 sequences within the liver quasispecies of a chronic hepatitis C patient never treated with
anti-NS3-protease inhibitors.
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Hepatitis C virus (HCV) infection, affecting 3% of the human
population (210 million people worldwide), has become one of
the leading causes of chronic hepatitis, end-stage liver disease,
and hepatocellular carcinoma. (Quer and Esteban, 2005). Like
most RNA viruses, HCV evolves rapidly due to high mutation
rates and high-level viral replication through an error-prone
RNA polymerase lacking proofreading capacity. Consequently,
in the infected individual, the viral population is composed of a
complexmixture of different but closely related genomes known
as quasispecies (Martell et al., 1992) whose shape is subject to
continuous changes due both, to competitive selection of con-
tinuously arising mutants (Domingo and Holland, 1988, 1994;
Duarte et al., 1994; Eigen and Biebricher, 1988; Holland et al.,
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doi:10.1016/j.virol.2007.10.006of variants with different phenotypes and fitness (Vignuzzi et al.,
2006). Among the numerous implications of the quasispecies
structure on the biology of RNA viruses, is that it predicts the
presence in any given patient of all possible genomic variants
carrying single nucleotide substitutions at each position,
conditioned to the relative fitness of each individual mutant.
The presence in a single host of all single mutants and double or
triple mutants depends on the viral load (with 4×104 particles all
simple mutants would be represented, with 1.6×109 particles all
double mutants and 6.4×1013 for all single, double and triple
mutants). With high-level HCV replication in the untreated pa-
tient (1012 new viral particles per day), point mutations at each
position in the genome arise at least once every day, so po-
tentially resistant mutants are constantly being generated.
Currently, the most effective treatment of persistent HCV
infection involves the combination of the nucleoside analogue
ribavirin with pegylated interferon alpha, which leads to a
sustained virological response in ∼50–55% of patients (less
than 40% of those infected with genotype 1 and over 80% of
those infected with HCV genotypes 2 or 3) (Fried et al., 2002),
(Manns et al., 2001). Because of the limited efficacy of this
Fig. 1. Alignment of the sequences that were different at the nucleotide level obtained from the liver of the protease-inhibitor untreated chronic HCV G1a patient.
The percentage at which each sequence was present in the isolate is shown at the end of each sequence. Dots indicate residues identical to those of the consensus
sequence. Mutations at position 156 that confer resistance to the protease inhibitors are highlighted (bold and italics) and marked in between two vertical lines that
limit the codon.
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239Rapid Communicationtreatment, selective inhibitors of the enzymatic activity of non-
structural proteins of the virus (NS3 protease, and NS5
polymerase) have been developed.Because the NS3 protease is essential for viral polyprotein
processing and, hence, productive HCV replication (Kolykha-
lov et al., 2000), several specific inhibitors (VX-950, SCH6 and
Fig. 1 (continued ).
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241Rapid CommunicationSCH503034) have been developed and are currently being
evaluated in clinical trials (BILN2061 despite reducing viremia
100–1000 fold in patients during phase Ib clinical trial, proved
cardiotoxic and its development was halted). However, as withHIV protease inhibitors, resistance to these inhibitors was
expected to become a major drawback of these new antiviral
agents. Indeed, treatment with the new inhibitors may induce
the appearance of resistant mutants which subsequently would
242 Rapid Communicationgain a selective growth advantage over the existing wild-type
viruses and rapidly become dominant in the viral quasispecies.
This has been demonstrated both in vitro (Neyts, 2006) and in
vivo during phase II clinical trials (Sarrazin et al., 2007). Selective
pressure in the replicon systemwithBILN2061 resulted in several
drug-resistant single mutations: A156T, R155Q and D168V (Lu
et al., 2004); similar results have been reported with VX-950 for
which substitutions A156V/T/S, V36A/M, T54A and R155K/T
induced different degrees of resistance (Wohnsland et al., 2007),
and also with SCH503034 for which mutations T54A, V170A
and A156S conferred low to moderate levels of resistance to
SCH503034, while A156T in the replicon system resulted in
high-level resistance to this compound and also to the related
ketoamide SCH446211 (SCH6) (Yi et al., 2006; Tong et al.,
2006a,b).
Here we report that sequences carrying the NS3-protease-
inhibitor resistant mutation A156T, were already present (at a
frequency of 0.78%) within the liver of an HCV-infected patient
who had never been treated with any of these protease inhibitors.
Results
A total of 128 independent clones from the NS3-protease
domain (567 nucleotides each) were obtained from the liver
biopsy of the anti-protease untreated patient. The population of
sequences at the nucleotide level was composed by a master
sequence that represented 70.31% (90/128), surrounded by a
cloud of mutants, one of them represented 3.91% (5/128),
another 2.34% (3/128), another 1.6% (2/128) and a group of
single mutants 21.9% (28/128) representing each one 0.78% (1/
128) (Fig. 1). The total number of individual mutations was 51
from a total of 72,576 nucleotides sequenced. The master and
consensus were identical.
At the amino acid level NS3-protease region was confirmed
to be a very well conserved region with 86% (110/128) of se-
quences equal, representing a master sequence that coincided
with the consensus one. Themaster sequence was surrounded by
three sequences with the same mutation that represented 2.3%
(3/128) of the population and 11.7% (15/128) of single point
mutants representing 0.78% each (Fig. 2). The total number of
mutations was 20 from a total of 24,192 amino acids studied.
The principal observation was the presence of mutation
A156T that exerts highly effective resistance in replicon system
studies to protease inhibitors BILN2061, VX950, SCH446211
and SCH503034 (Yi et al., 2006). In the mutant named B6b-
2006 the codon GCC (Ala) changed to ACC (Thr). Mutation in
this codon did not seem to be a rare event since another clone
B3b-2006 already had a single point mutation but in the third
position GCA (Ala) that does not generate an amino acid
change (Figs. 1 and 2).
Discussion
Appearance of mutants resistant to anti-NS3-protease treat-
ment has been reported in vitro using the replicon system and
during treatment, but the presence of such mutants in a patient
has not been shown before starting treatment. Here we reportthat NS3-protease-inhibitor resistant mutant, A156T, was al-
ready present at 0.78% in the infected liver of an HCV-infected
patient who had never been treated with any of these protease
inhibitors. Previous estimations of HCV production showed an
average of 1.3×1012 HCV virions produced per day (Neumann
et al., 1998), with 4 to 25% (average of 14%) of the 2×1011
hepatocytes per liver had replicative-intermediate RNA (Chang
et al., 2000), and an average number of viral genomes per
productively infected hepatocyte of 33 (7 to 64) (Chang et al.,
2003). The total HCV genomic RNA in the liver has been
estimated to range from 1.3×108 to 1.3×109 RNA molecules
per g of liver tissue. Following these estimations together with
our data that 0.78% of sequences are carrying the protease-
inhibitor resistant mutation A156T in our untreated patient, it
suggests that at the time of analysis, between 1×106–1×107
RNA molecules per gram of liver tissue may be carrying this
particular mutation, which is not negligible.
Mutation frequency is defined as the proportion of mutation
positions relative to the consensus nucleotide/amino acid se-
quence and it is calculated by dividing the number of mutations
relative to the consensus by the total number of nucleotide/amino
acid sequences. We compared the average mutation frequency of
the HCV NS3-protease region with mutation frequency in
previously described codons directly or indirectly involved in
drug resistance (amino acid V36, T54, R109, R155, A156, D168
and V170 and compensatory mutations Q86, P89 and G162). No
statistically significant differences were found. Average mutation
frequency andmutation frequencies found in residues of unknown
drug resistance was 0.7×10−3 at the nucleotide level and
0.83×10−3 at the amino acid level, while mutation frequencies
at residues related to drug resistance were 0.52×10−3 and
0.78×10−3 respectively. Therefore, since mutation frequencies at
the codons related to resistance are comparable to the average, it is
expected that, for statistical reasons, mutations will occasionally
affect the drug-resistant codons and relevant substitutions, as the
A156Tmutation here reported, will appear by randommutation in
the absence of selection by the inhibitor. At present, we are not
able to differentiate whether naturally occurring A156T mutant
was replicating in the liver or was just a simple probabilistic recent
event during viral replication of the wild type.
The fact that sequence with mutation A156T represents as
much as 0.78% of the liver viral population despite the sig-
nificant reduction of HCV-NS3/4A catalytic efficiency, poly-
protein processing, and replication fitness (Tong et al., 2006a)
requires further explanation. Fitness of a viral population de-
pends on multiple factors that are affecting viral replication
(from hepatocyte metabolism, to the immune pressure) and this
may be different from patient to patient and in vitro depending
on the cell culture conditions. It has been described that mu-
tations that largely compensate for fitness reduction often arise
(Escarmis et al., 1999). It has been recently reported that three
separate second-site mutations P89L, Q86R, and G162R were
capable of partially reversing A156T defects in polyprotein
processing and/or replicon fitness without reducing resistance to
protease inhibitor (Yi et al., 2006). Our mutant A156T and also
all sequences isolated from liver of patient studied, had changes
at positions 89 and 86 (P89Q and Q86P). Since these two
Fig. 2. Alignment of the sequences that were different at the amino acid level. Dots indicate residues identical to those of the consensus sequence. The percentage at
which each sequence was present in the isolate is shown at the end of each sequence. Dash indicates STOPmutation. Arrow caps indicate important amino acid changes
such as STOP codons, mutation A156T, mutations P89Q, Q86P and mutation D81A that belongs to the catalytic triad H57, D81 and S139. Clonal sequences are
identified with the clonal descriptor and the year 2006 when liver biopsy of the chronic patient was obtained.
243Rapid Communicationmutations have been fixed in the quasispecies of our patient, a
selective advantage for the mutant carrying them may exist.
Taking all together, the most plausible explanation for the
presence in 0.78% of the viral population of A156T mutant is
that, mutations P89Q and Q86P might compensate for A156T-
associated fitness decrease. Therefore, the presence of putative
compensatory mutations in all viral liver sequences may have
facilitated the random appearance of the A156T mutant, which
might otherwise have been negatively selected in the absence of
protease-inhibitors treatment. The compensatory fitness effect
of these mutations however, would require in vitro confirma-
tion. On the other hand, originally described compensatory
mutations P89L and Q86R along with the A156T, if present,
would require sequencing 6.4×1013 clones to be demonstrated,
in the absence of drug treatment.
The presence of drug-resistant RNA viruses from natural
isolates in untreated patients is not a rare event and has been
previously reported for several other viruses, specially in the
case of antiretroviral-resistant HIV-1 (Najera et al., 1995; Mohri
et al., 1993), and including acyclovir-resistant herpes simplex
virus (Parris and Harrington, 1982), drug-resistant Citomegalo-virus (Liu et al., 2000) and also lamivudine-resistant HBV
(Kobayashi et al., 2001). Preexistence of such drug-resistant
viruses in an untreated patient is a direct consequence of the
quasispecies structure of RNA viruses with the continuous gen-
eration of variants, and represents an important drawback in the
treatment of viral diseases (Duarte et al., 1994; Domingo and
Holland, 1992). In our study, mutation A156Tconfers high-level
resistance to drug inhibitors BILN2061, VX-950, SCH446211
and SCH503034. Therefore any combination therapy using only
protease inhibitors, is predicted to be inescapably deemed to
failure, opening important ethical considerations in monother-
apy treatments and suggest that compounds targeting different
regions should be used in combination (Domingo, 1989), to
decrease the likelihood of resistance, or in combination with
other antivirals like interferon and ribavirin.
Patients and methods
Patient A was a 28-year old man with a history of Intra-
venous drug use who was found to be anti-HCV positive at the
time of a volunteer blood donation in 1993, and prospectively
244 Rapid Communicationfollowed since that time (Quer et al., 2003). He had persistent
HCV infection with a genotype 1a as confirmed by sequencing
of 5′UTR, E2PePHD and NS3 regions and a viral load in serum
of 106 IU/mL. A liver biopsy showed moderate chronic active
hepatitis and he received treatment with standard interferon and
ribavirin (IFN+RBV) for 12 months (between February 1996
and March 1997) with transient biochemical but no virological
response. Subsequently, he had not been given further treat-
ment. He underwent a follow up liver biopsy in November 2006
and excess tissue not needed for routine histological assessment
was immediately embedded in RNA later (Ambion Cambridge-
shire, UK) for 24 h prior to criopreservation at −80 °C.
RNA-extraction, nested RT-PCR using pairs of primers
A5319ds 5′CAGGACGCCGCCAACGAGCACCCA3′
A3349us 5′TGACATCATCAACGGCTTGCCTGTTTC 3′, in-
ternal primers and A47us (up): 5′GCGCCCATCACGGCG-
TACGCCCA3′ and p871ds (down): 5′GCATCCGTG-
GAGTGGCACTC3′, for nested PCR.
To minimize misincorporation errors during PCR amplifica-
tion, we used the high-fidelity DNA polymerase Pfu (Stratagene,
San Diego, CA, USA) which, under the conditions used, has a
reported error rate between 1.3×10−6 (Cline et al., 1996) and
6.5×10−7 (Andre et al., 1997). After 70 cyles of amplification,
the expected number of mutation in the worse reported case is 1
error in 9.1×105 nucleotides sequenced. In our study, after
sequencing 45,432 nucleotides, the expected number of errors
due to Pfu is 0.5. Besides, a control study has been carried out
and one of the clones (1893 nucleotides) of known sequence,
was subjected to 70 additional cycles of PCR in 20 independent
amplifications. Nomutations were detected after analyzing 8140
nucleotides. This result improves our previous estimates of the
misincorporation rate when using a more error-prone polymer-
ase, Taq DNA polymerase (Perkin-Elmer) (1/5451 and 2/9964)
(Cabot et al., 2001; Martell et al., 1992), and confirms that most
of the observed heterogeneity was independent of artifact during
the amplification procedure (Quer et al., 2005). GenBank
accession numbers for different sequences are EF613694 to
EF613725.
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